Title: A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)1

Study Director: Michael Kauffman, MD, PhD, Karyopharm Therapeutics Inc

Continue Reading

Description: For this double-blind, multi-center, randomized phase 2/3 trial (ClinicalTrials.gov Identifier: NCT02606461), researchers are evaluating the safety and efficacy of selinexor, an orally administered inhibitor of CRM1, among patients with unresectable dedifferentiated liposarcoma.

In the phase 2 portion of this trial, an estimated 100 patients will be randomly assigned 1:1 to selinexor or placebo; in the phase 3 portion, an estimated 195 patients will be randomly assigned 2:1 to selinexor or placebo.

The primary endpoint is progression-free survival. Total estimated enrollment is 245 patients.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit  https://clinicaltrials.gov/ct2/show/NCT02606461.

Status: This study is open and recruiting patients as of July 28, 2017.

This study is sponsored by Karyopharm Therapeutics Inc.

Reference

  1. Clinicaltrials.gov. Selinexor in advanced liposarcoma (SEAL) .   NCT02606461.  https://clinicaltrials.gov/ct2/show/NCT02606461. Accessed July 28, 2017.